Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | EED | O75530 | 8/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668673 | 1.00 | TAAR1 (0.41) | TAAR1EEDGAAKDM4EBACE1 | |
| SCHEMBL1241666 | 0.83 | L3MBTL1 (0.37) | TAAR1ALDH1A1 | |
| SCHEMBL723742 | 0.83 | TAAR1 (0.48) | TAAR1GAAKDM4EBACE1DAO | |
| SCHEMBL4243083 | 0.79 | EED (0.41) | TAAR1EEDGAAKDM4EALDH1A1 | |
| SCHEMBL29386736 | 0.79 | EED (0.41) | TAAR1EEDGAAKDM4EALDH1A1 | |
| SCHEMBL7627111 | 0.77 | TAAR1 (0.45) | TAAR1EEDGAABACE1 | |
| SCHEMBL31614296 | 0.77 | EED (0.43) | TAAR1EEDGAAKDM4EALDH1A1 | |
| SCHEMBL15352403 | 0.77 | EED (0.40) | TAAR1EEDGAAKDM4EDAO | |
| SCHEMBL20558278 | 0.77 | EED (0.40) | TAAR1EEDGAAKDM4EALDH1A1 | |
| SCHEMBL14144306 | 0.77 | EED (0.43) | TAAR1EEDGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110536885-B | Process for producing difluoromethylene compound | 佐藤制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-3551626-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2023-10-25 | — | — | EP | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-11084792-B2 | Method for producing difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3617197-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| CN-101910169-A | Bicyclic amine derivatives | EISAI R&D MAN CO LTD | 2010-12-08 | — | — | CN | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| CN-1651142-A | Catalyst component used for ethylene oligomerization, preparing process and application thereof | DAQING PETROCHEMICAL BRANCH CO (CN) | 2005-08-10 | — | — | CN | disclosed |
| CN-1108193-C | Novel catalyst for ethylene trimerization, its preparation process and application | RES INST BEIJING YANSHAN PETRO (CN) | 2003-05-14 | — | — | CN | disclosed |
| CN-1256968-A | Novel catalyst for ethylene trimerization, its preparation process and application | RES INST BEIJING YANSHAN PETRO (CN) | 2000-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | TAAR1 949/4885EED 1930/4885GAA 92/4885 |
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | HACL2, MGLL, ABL1 | TAAR1 220/4885EED 4075/4885GAA 1891/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | TAAR1 1459/4885EED 1075/4885GAA 2829/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | TAAR1 1715/4885EED 3794/4885GAA 1697/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | TAAR1 543/4885EED 1928/4885GAA 4207/4885 |
| US-11084792-B2 | Method for producing difluoromethylene compound | HACL2, MGLL, ABL1 | TAAR1 220/4885EED 4075/4885GAA 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.